1. Home
  2. ANIX vs NCSM Comparison

ANIX vs NCSM Comparison

Compare ANIX & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.49

Market Cap

119.8M

Sector

Health Care

ML Signal

HOLD

Logo NCS Multistage Holdings Inc.

NCSM

NCS Multistage Holdings Inc.

HOLD

Current Price

$51.00

Market Cap

127.5M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
NCSM
Founded
1982
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oilfield Services/Equipment
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
127.5M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
ANIX
NCSM
Price
$3.49
$51.00
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
209.9K
3.3K
Earning Date
05-27-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
239.22
EPS
N/A
N/A
Revenue
$210,000.00
$142,471,000.00
Revenue This Year
N/A
$5.57
Revenue Next Year
N/A
$4.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$34.06
52 Week High
$5.46
$87.36

Technical Indicators

Market Signals
Indicator
ANIX
NCSM
Relative Strength Index (RSI) 58.73 58.29
Support Level $2.73 $42.69
Resistance Level $3.89 $51.69
Average True Range (ATR) 0.20 0.85
MACD 0.01 -0.08
Stochastic Oscillator 69.92 75.92

Price Performance

Historical Comparison
ANIX
NCSM

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About NCSM NCS Multistage Holdings Inc.

NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.

Share on Social Networks: